Sigilon Therapeutics is a clinical stage biotechnology company that aims to develop functional cures for chronic diseases, such as Hemophilia A, mucopolysaccharidosis type 1, Fabry disease, and type 1 diabetes. Its lead product candidate is SIG-001, currently in Phase I/II clinical trials, for preventing bleeding episodes in patients with Hemophilia A. The company has a research collaboration and license agreement with Eli Lilly and Company.